Biomarker Strategies for Chemotherapy Cardiotoxicity: Promise Versus Validation

This narrative review consolidates traditional and emerging molecular indicators for early detection of chemotherapy-induced cardiotoxicity, clarifying which biomarkers are guideline-endorsed and which remain investigational for cardio-oncology practice.

📅 Journal publication: Feb 2026 (online Feb 25, 2026) · Last updated: Jul 15, 2026

anthracyclinesdoxorubicintrastuzumabHER2 inhibitorsVEGF inhibitorsimmune checkpoint inhibitorscardiotoxicitycardiac troponinnatriuretic peptidesGDF-15galectin-3sST2cardio-oncologynarrative reviewbiomarkers Oncology Pharmacy

Background Information

New biomarkers offer promise for early detection of chemotherapy-induced heart damage.

Chemotherapy-induced cardiotoxicity (CIC) can significantly impact the long-term health of cancer survivors by causing heart-related complications. Emerging biomarkers such as inflammatory cytokines, fibrosis-related proteins, and non-coding RNAs can provide earlier detection and risk stratification for CIC than traditional markers. While new biomarkers show promise, their clinical use is limited by population study variability; integration with imaging and standardized protocols is needed for effective surveillance. A multiparametric approach may enhance the precision monitoring of chemotherapy-induced cardiotoxicity.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.

Subscribe for $8/month → Read this one free →

Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Kong Y, He R, He H, Liao L, Wu C, Chen X, Peng X

Citation: Kong Y, He R, He H, et al. Precision Monitoring Strategies for Chemotherapy-Induced Cardiotoxicity: A Review of Molecular Indicators for Early Detection and Risk Stratification. Reviews in cardiovascular medicine. 2026;27(2):45852. doi:10.31083/RCM45852

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Founding member rate

$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →

Free account, no credit card. Includes 1 full deep analysis every month.

Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.